Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
This immunotherapy drug helped me beat cancer - instead of $229k it now costs $31
A life-changing medication that gave a young Sydney woman with rare blood cancer a second chance has been approved for PBS listing 10 times faster than average, giving patients greater treatment ...
heraldsun.com.au6d
This immunotherapy drug helped me beat cancer - instead of $229k it now costs $31
Associate Professor Shaun Fleming said the listing of Blincyto meant patients could avoid the potentially fatal side effects of chemotherapy. “Typically, patients with ALL are being treated with ...
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Q1 Earnings Forecast for Amgen Issued By William Blair
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
pharmaphorum3d
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.
pharmaphorum1d
Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU
Meanwhile, Amgen's bispecific antibody Blincyto (blinatumomab) also targets CD19 but is indicated for acute lymphoblastic leukaemia (ALL). CAR-Ts can be highly effective but are made by harvesting ...